Edgewise reports strong Q2 2026 results, completes sale of sevasemten business
Edgewise announced positive Phase 2 CIRRUS-HCM data for EDG-7500 and finalized the sale of sevasemten to Servier for up to $2.65 billion, significantly boosting its balance sheet and strategic focus.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day